NOVATO, Calif., July 13, 2026 /PRNewswire/ -- Lighthouse Pharmaceuticals today announced new analyses from the Phase 2/3 GAIN trial demonstrating that atuzaginstat, a gingipain inhibitor targeting Porphyromonas gingivalis (Pg), was associated with benefits in several neuropsychiatric...
Hence then, the article about lighthouse pharmaceuticals reports new evidence that gingipain inhibition benefits neuropsychiatric symptoms and reduces caregiver distress in p gingivalis positive alzheimer s disease at aaic 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026 )
Also on site :
- Shakira Says Her Upcoming Madrid Residency Was Born From Seeing Latinos “Persecuted” and Living in Fear
- Keith Richards Wrote One of the Rolling Stones’ Biggest Hits During One of the Darkest Moments of His Life
- 1987 Hysteria Hit, Written by Accident After Def Leppard Finished Their Album, Became Joe Elliott’s ‘Beatles Song’